Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 10/20 | 0.55 |
| ▸ | CDK2 | P24941 | 10/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.55 |
| ▸ | AURKA | O14965 | 6/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.46 |
| ▸ | EP300 | Q09472 | 4/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5720863 | 0.83 | CCNA2 (0.46) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL2920481 | 0.80 | CCNA2 (0.68) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL5720872 | 0.77 | GRM5 (0.46) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL5720802 | 0.76 | BRD4 (0.62) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL4020705 | 0.72 | CCNA2 (0.55) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL4484878 | 0.72 | CCNA2 (0.49) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL2921269 | 0.71 | AURKA (1.00) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL2920484 | 0.70 | CCNA2 (0.45) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL2915619 | 0.70 | CCNA2 (0.50) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL16123821 | 0.70 | CCNA2 (0.53) | CCNA2CDK2CCNA1AURKACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135508-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-06-22 | — | — | US | disclosed |
| EP-1527074-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004013144-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA SPA (IT) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135508-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K5, MAP3K19 | CCNA2 915/4885CDK2 52/4885CCNA1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.